

**Table 6. Safety results from clinical trials**

Primary outcome								
Clinical Trials	EPHESUS 2000		PENTATHLON 2000		PENTAMAKS 1999		PENTHIFRA 1999	
	Fondaparinux N=1140	Enoxaparin N=1133	Fondaparinux N=1128	Enoxaparin N=1129	Fondaparinux N=517	Enoxaparin N=517	Fondaparinux N=831	Enoxaparin N=842
Fatal bleeding	0	0	0	0	0	0	0	1 (0.1%)
Bleeding in critical organ	0	0	0	1 (0.1%)	0	0	0	0
Bleeding leading to reoperation	5 (<1%)	3 (<1%)	2 (0.2%)	2 (0.2%)	2 (0.4%)	1 (0.2%)	3 (0.4%)	2 (0.2%)
Bleeding with a bleeding index >2	42 (4%)	29 (3%)	18 (1.6%)	8 (0.7%)	9 (1.7%)	0	15 (1.8%)	16 (1.9%)
Secondary Outcome								
Clinical Trials	EPHESUS 2000		PENTATHLON 2000		PENTAMAKS 1999		PENTHIFRA 1999	
	Fondaparinux N=1140	Enoxaparin N=1133	Fondaparinux N=1128	Enoxaparin N=1129	Fondaparinux N=517	Enoxaparin N=517	Fondaparinux N=831	Enoxaparin N=842
Transfusions	714 (63%)	690 (61%)	593 (53%)	555 (49%)	222 (42.9%)	197 (38.1%)	34 (4.1%)	18 (2.1%)
Blood transfusions units among patients transfused for volume replacement	2 (1-10)	2 (1-10)	2 (1-8)	2 (1-9)	1.9 ± 1.1	1.8 ± 0.9	2.7 ± 1.5	2.8 ± 1.8
Death from any cause	0	2 (0-2%)	3 (0.3%)	1 (0.1%)	1 (0.4%)	2 (0.4%)	11 (1.3%)	16 (1.9%)